Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed trials have results

Key Signals

4 recruiting2 with results

Enrollment Performance

Analytics

Phase 1
5(62.5%)
Phase 2
3(37.5%)
8Total
Phase 1(5)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT03334305Phase 1Terminated

Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas

Role: collaborator

NCT02945800Phase 2Completed

Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma

Role: collaborator

NCT07194044Phase 1Recruiting

Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

Role: collaborator

NCT05660408Phase 1Active Not Recruiting

RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors

Role: collaborator

NCT06701812Phase 2Recruiting

Digoxin Medulloblastoma Study

Role: collaborator

NCT06423950Recruiting

Generating Novel Translational and Therapeutic Strategies Based on a Multicenter, Pediatric and AYA Evolutionary Tumor Board (pedsETB)

Role: collaborator

NCT05634369Phase 1Recruiting

A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue

Role: collaborator

NCT04388839Phase 2Active Not Recruiting

Evolutionary Therapy for Rhabdomyosarcoma

Role: collaborator

NCT03600649Phase 1Unknown

Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Role: collaborator

All 9 trials loaded